The short version of GHS-R1a fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
== Pharmacodynamics == Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) receptor agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. Liraglutide leads to insulin release in pancreatic beta cells in the presence of elevated blood glucose. This insulin secretion subsides as glucose concentrations decrease and approach euglycemia (normal blood glucose level). It also decreases glucagon secretion in a glucose-dependent manner and delays gastric emptying. Unlike endogenous GLP-1, liraglutide is stable against metabolic degradation by peptidases, with a plasma half-life of 13 hours.
=== Prepared solutions === Prepared solutions generally consist of water and electrolytes; glucose, amino acids, and lipids; essential vitamins, minerals and trace elements are added or given separately. Previously lipid emulsions were given separately but it is becoming more common for a "three-in-one" solution of glucose, proteins, and lipids to be administered.
=== Biomaterials === Hydrogels are three-dimensional network structures with high hydrophilicity that can absorb and retain large amounts of water. Due to their excellent biocompatibility, they are widely used in the field of biomaterials. The main feature of hydrogels is their high water content, which is similar to the aqueous environment in biological systems, making them ideal for applications in tissue engineering, drug delivery, wound dressings, and artificial skin. Hydrogels can be classified into natural and synthetic types. Natural hydrogels, such as gelatin and chitosan, are derived from biological materials and offer good biodegradability and biocompatibility. Synthetic hydrogels, on the other hand, typically have higher mechanical strength and tunability but may exhibit lower biocompatibility. Additionally, hydrogels can be categorized as environmental-responsive or non-responsive based on their response to external stimuli. Environmental-responsive hydrogels, which can react to changes in temperature, pH, or ion concentration, are particularly useful in drug delivery systems. Due to their tunability, hydrogels continue to expand their applications in the biomedical field and are expected to play a crucial role in various medical applications in the future. Implanted or injected hydrogels have the potential to support tissue regeneration by mechanical tissue support, localized drug or cell delivery, local cell recruitement or immunomodulation, or encapsulation of nanoparticles for local photothermal therapy or brachytherapy.
The lunula is the crescent-shape area at the base of the nail, lighter in color as it mixes with matrix cells. Only primates have nails. In other vertebrates, the keratinizing system at the terminus of each digit produces claws or hooves. The epidermis of vertebrates is surrounded by two kinds of coverings, which are produced by the epidermis itself. In fish and aquatic amphibians, it is a thin mucus layer that is constantly being replaced. In terrestrial vertebrates, it is the stratum corneum (dead keratinized cells). The epidermis is, to some degree, glandular in all vertebrates, but more so in fish and amphibians. Multicellular epidermal glands penetrate the dermis, where they are surrounded by blood capillaries that provide nutrients and, in the case of endocrine glands, transport their products.
Two distinct but related processes are considered to be involved in the development of obesity: sustained positive energy balance (energy intake exceeding energy expenditure) and the resetting of the body weight "set point" at an increased value. The second process explains why finding effective obesity treatments has been difficult. While the underlying biology of this process still remains uncertain, research is beginning to clarify the mechanisms. At a biological level, there are many possible pathophysiological mechanisms involved in the development and maintenance of obesity. This field of research had been almost unapproached until the leptin gene was discovered in 1994 by J. M. Friedman's laboratory. While leptin and ghrelin are produced peripherally, they control appetite through their actions on the central nervous system. In particular, they and other appetite-related hormones act on the hypothalamus, a region of the brain central to the regulation of food intake and energy expenditure. There are several circuits within the hypothalamus that contribute to its role in integrating appetite, the melanocortin pathway being the most well understood. The circuit begins with an area of the hypothalamus, the arcuate nucleus, that has outputs to the lateral hypothalamus (LH) and ventromedial hypothalamus (VMH), the brain's feeding and satiety centers, respectively. The arcuate nucleus contains two distinct groups of neurons.
Sources: en.wikipedia.org
== Female viceregal representatives == Below are women who have been appointed representatives of heads of state, such as female governors-general and French representatives of Andorra. As governors-general are appointed representatives of the monarch of the Commonwealth realms (currently Charles III) and the French Representatives of Andorra are appointed representatives of the French Co-Prince of Andorra (currently Emmanuel Macron), they act as heads of state and carry out on a regular basis the functions and duties associated with such a role in the Commonwealth realms (excluding the United Kingdom, which has no governor-general, as the monarch of the Commonwealth realms primarily resides there) and Andorra, respectively.
=== EC 2.10: metal transferases === The category of EC 2.10 includes enzymes that transfer molybdenum or tungsten-containing groups. However, as of 2011, only one enzyme has been added: molybdopterin molybdotransferase. This enzyme is a component of MoCo biosynthesis in Escherichia coli. The reaction it catalyzes is as follows: adenylyl-molybdopterin + molybdate
It has become clear that the West in general and America in particular have an unspeakable hatred for Islam. [...] It is the hatred of crusaders. Terrorism against America deserves to be praised because it was a response to injustice, aimed at forcing America to stop its support for Israel, which kills our people. [...] We say that the end of the United States is imminent, whether bin Laden or his followers are alive or dead, for the awakening of the Muslim ummah [nation] has occurred. [...] It is important to hit the economy [of the U.S.], which is the base of its military power... If the economy is hit, they will become reoccupied. In a 2002 manifesto, he listed multiple factors implied to have motivated 9/11, including U.S. support of Israel against Lebanon during their occupation of Southern Lebanon and Palestinians during the Second Intifada, support of the Philippines against Muslim militants, support of Russia against Muslim militants, and support of India against Muslim civilians in Kashmir. He also listed the former U.S.-led intervention against Muslim militants in Somalia, pollution caused by the U.S., and the U.S.' refusal to ratify the Kyoto Protocol. In the 2004 video, he said he was inspired to destroy the World Trade Center's Twin Towers after watching the destruction of towers in Lebanon by Israel during the 1982 Lebanon War.
=== Proton beam writing === Proton beams can be used for writing (proton beam writing) through either the hardening of a polymer (by proton induced cross-linking), or through the degradation of a proton sensitive material. This may have important effects in the field of nanotechnology.
== History == Jasons Market Place started its business in Singapore in 1975. It was introduced in Taiwan in 2003. In 2007, it opened in Hong Kong's Jardine's Lookout under the name "Market Place by Jasons". In 2012, Jasons Food Hall began operations in the Bangsar Shopping Centre, an upmarket shopping mall in the township of Bangsar, Malaysia, as a replacement for a Cold Storage store. Jasons Market Place in Taiwan was sold to Carrefour in 2020 and rebranded as Mia C'bon from 2022.
Sources: en.wikipedia.org
Muslims, India's largest religious minority, have contributed significantly to a synthetic Indo-Islamic religious culture. Sufism, the heterodox mystical movement in Islam found receptiveness among adherents of the medieval regional Shaivite and Vaishnavite traditions of Bhakti. Sikh gurdwaras and Sufi dargahs often attract both visitors and worshippers from other religions. India has monastic traditions such as that of Jain ascetics some of whom practice an extreme form of nonviolence (ahimsa) and Buddhist communities that have preserved ancient styles of meditations. This religious diversity coexists with religious endogamy—people rarely marry outside their faith. There is also religious segregation in housing—religious groups cluster by choice or necessity. Thus, India's religious picture has both rich intermixing and clear divisions.
Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics. In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis. In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient. The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders. A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics. In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.
amination (see Figure) The C-terminus can also be blocked (thus, neutralizing its negative charge) by amination. glycosyl phosphatidylinositol (GPI) attachment Glycosyl phosphatidylinositol(GPI) is a large, hydrophobic phospholipid prosthetic group that anchors proteins to cellular membranes. It is attached to the polypeptide C-terminus through an amide linkage that then connects to ethanolamine, thence to sundry sugars and finally to the phosphatidylinositol lipid moiety. Finally, the peptide side chains can also be modified covalently, e.g.,
== Medical uses == Phenibut is used in Russia, Ukraine, Belarus and Latvia as a pharmaceutical drug to treat anxiety and to improve sleep (e.g., in the treatment of insomnia). It is also used for various other indications, including the treatment of asthenia, depression, alcoholism, alcohol withdrawal syndrome, post-traumatic stress disorder, stuttering, tics, vestibular disorders, Ménière's disease, dizziness, for the prevention of motion sickness, and for the prevention of anxiety before or after surgical procedures or painful diagnostic tests.
== Products == IMA Life's production range includes machines for vial washing and sterilising, filling and stoppering machines for aseptic environments, filling and closing machines for pharmaceuticals, microdosing machines for aseptic powder filling, labellers, blowing machines, depackers and tray loaders. IMA Life also offers freeze-drying technology: industrial, pilot and laboratory freeze dryers. IMA Life designs, manufactures, installs and services integrated systems predominantly for the pharmaceutical primary packaging market. It has been in the market of freeze dryer manufacturing for more than 50 years. It specializes in the production of industrial freeze dryers (lyophilizers)and fully automated loading & unloading systems.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.